KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Equity Average (2016 - 2025)

Charles River Laboratories International (CRL) has 15 years of Equity Average data on record, last reported at $3.3 billion in Q4 2025.

  • For Q4 2025, Equity Average fell 9.43% year-over-year to $3.3 billion; the TTM value through Dec 2025 reached $3.3 billion, down 9.43%, while the annual FY2025 figure was $3.3 billion, 6.19% down from the prior year.
  • Equity Average reached $3.3 billion in Q4 2025 per CRL's latest filing, down from $3.4 billion in the prior quarter.
  • Across five years, Equity Average topped out at $3.8 billion in Q3 2024 and bottomed at $2.2 billion in Q1 2021.
  • Average Equity Average over 5 years is $3.0 billion, with a median of $3.2 billion recorded in 2023.
  • Peak YoY movement for Equity Average: surged 32.21% in 2021, then decreased 11.03% in 2025.
  • A 5-year view of Equity Average shows it stood at $2.5 billion in 2021, then increased by 13.06% to $2.8 billion in 2022, then increased by 23.14% to $3.5 billion in 2023, then grew by 4.93% to $3.6 billion in 2024, then decreased by 9.43% to $3.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $3.3 billion in Q4 2025, $3.4 billion in Q3 2025, and $3.3 billion in Q2 2025.